Fusion genes, particularly those involving kinases, have been demonstrated as drivers and are frequent 1 3 therapeutic targets in cancer 1 . Here, we describe our results on detecting transcript fusions across 33 1 4
cancer types from The Cancer Genome Atlas (TCGA), totaling 9,966 cancer samples and 648 normal 1 5 samples 2 . Preprocessing, including read alignment to both genome and transcriptome, and fusion 1 6 detection were carried out using a uniform pipeline 3 . To validate the resultant fusions, we also called 1 7 somatic structural variations for 561 cancers from whole genome sequencing data. A summary of the 1 8
data used in this study is provided in Table S1 . Our results can be accessed per our portal at 1 9 http://www.tumorfusions.org. 2 0
We identified 56,198 and 3,838 candidate fusions in 9,966 cancer and 648 non-neoplastic 2 1 samples, respectively. After applying stringent filters controlling for sequence similarity of the partner 2 2 genes, transcriptional allelic fraction, dubious junctions, germline events, and presence in non-2 3 neoplastic tissue, we obtained 20,731 high confident fusion events (Table S1), 54% of which were 2 4
supported by at least one DNA breakpoint near the fusion junction per the matching Affymetrix SNP6 2 5
DNA copy number data profile. Frequent germline fusions between adjacent genes such as between 2 6 CRHR1 and KANSL1 on chr17q (n=36, 6%) or TFG and GPR128 (n = 9, 1%) on chr3q12.2 were 2 7
frequently associated with focal copy number changes and were likely the result of germline 2 8 polymorphisms 4 . We compared fusions with somatic structural variations (SVs) detected using whole 2 9 genome sequencing from 561 cancer samples, which associated 1,679 of 2,585 fusions (65%) to SVs. 3 0
Of these, the majority were translocations (50%), followed by transcript fusions as a result of deletions 3 1 (20%), inversions (20% or duplication (10%) (Figure S1 ). While 57% of fusions (n=962) mapped to a 3 2 single SV, 21% (n=348) were associated with three or more SVs. Such fusion events likely resulted 3 3 from complex DNA rearrangement events. We found a significant enrichment for chromosome arm 12q 3 4 fusions in sarcoma (adjusted p<0.001, Chi-square test) ( Figure S2) , seen previously in glioblastoma 5 . 3 5
The 12q13-15 growth factor signaling gene FRS2 was frequently involved as the 5' partner ( Figure S3 ), 3 6 nominating FRS2 as a relevant target in this disease 6 . Pertaining to the number of sarcomas with a 3 7 complex 12q (21%), this cancer showed enrichment for cases with an excessive number of transcript 3 8 fusions (9% in sarcoma vs 2% in other cancers, p= 1.78e-21, Chi-square test; Figure S4 ). 3 9
The majority of the 20,731 fusions were singletons (n = 17,238, 83.2%). Amongst the 1,205 4 0 recurrent fusions, 850 were found in only two cases. These data suggest that gene fusions are 4 1 frequently not selected for but represent collateral DNA rearrangement damage. The most frequent 4 2 recurrent fusions were lineage specific, such as TMPRSS2-ERG in prostate cancer, CCDC6-RET in 4 3 thyroid cancer, and PML-RARA and CBFB-MYH1 in acute leukemia. In contrast FGFR3-TACC3 (n = 4 4 36), PTPRK-RSPO3 (n = 9) and EML4-ALK (n = 7) were found across multiple originating tissues 4 5
( Figure 1A) . Breaking fusions down into their separate gene partners, we found that other than 4 6
TMPRSS2 and ERG, recurring fusion partner genes were usually found in more than one tissue of 4 7 origin ( Figure 1B) . TRK fusions, targeting of which by larotrectinib has recently shown promising 4 8 clinical efficacy 7 , were found in 28 cases across 11 cancer types. Other fusions with potential clinical 4 9 9
Identification of fusion transcripts 1 0 0
We applied PRADA 3 to all RNAseq samples for data preprocessing and fusion calling. In brief, RNA 1 0 1 sequencing reads were aligned to a composite reference consisting of both genome (hg19) and 1 0 2 transcriptome (Ensembl 64), followed by a remapping step that aligns transcriptome coordinates to the 1 0 3 reference genome 15 . GATK best practices were implemented in the pipeline, including marking 1 0 4
duplication and base quality recalibration. More information about PRADA can be found at 1 0 5 http://bioinformatics.mdanderson.org/main/PRADA:Overview. 1 0 6
PRADA detects fusion transcripts based on discordant read pairs (reads mapping to different 1 0 7
protein-coding genes) and junction spanning reads (reads mapping to the exon-exon junctions). We 1 0 8 required at least two discordant read pairs and one junction spanning read to call a fusion candidate. All 1 0 9 fusion candidates were collected and were subject to additional filtering. The filters were described as 1 1 0 follows: (1) candidates observed in normal controls were removed; (2) candidates with highly similar 1 1 1 partners in sequence (blastn e-value≤0.001) were removed; (3) candidates with low 1 1 2 transcriptional allelic fraction were removed (TAF, minimum 0.01 for both partner genes); (4) 1 1 3 candidates with very promiscuous partner genes were removed (the Partner Gene Variety filter, see 1 1 4 below); (5) Candidates with identical junctions in more than 15 samples were removed; (6) candidates 1 1 5
with supporting reads mapped disproportionately to sense and antisense strands were removed. 1 1 6
Transcriptional allelic fraction (TAF) was calculated as the ratio of fusion supporting junction spanning 1 1 7
reads to the total number of reads spanning the junction involved in the fusion. Partner Gene Variety 1 1 8
(PGV) was defined as the number of unique chromosomal arms where the partner genes were found. A 1 1 9
higher PGV suggests a gene was found to fuse with more partner genes in a cancer lineage. For genes 1 2 0 with PGV greater than 10, we used permutations (n=100,000) to model the background distribution of 1 2 1 the random chances of obtaining the observed PGV (empirical p value). We removed fusions with 1 2 2 empirical p value less than 0.001%. For filter (6), we hypothesized that ratio of sense and antisense 1 2 3 strand mapping reads was proportional to the distance from the start of the fusing transcript to the 1 2 4 junctions of the two partner genes. Since lower coverage and short distance may confound this ratio, 1 2 5
we limited our filtering to fusions with more than 100 spanning reads and such distance more than 500 1 2 6 base pairs. We removed fusions that had this ratio greater than 100. 1 2 7
To establish a positive control fusion list, we integrated three resources including Mitelman 16 , 1 2 8
ChimerPub 17 , and Cosmic fusions 18 . Fusions reported in all three independent references were curated 1 2 9
as a list of known fusions (n=321). Of these 321, 38 fusions were detected in our data set reflecting 359 1 3 0 instances in total. 1 3 1 1 3 2
Validation of fusion transcripts through integrating structure variants and copy number changes 1 3 3
For cases where both copy number profile and gene fusion were available, we aligned fusion junctions 1 3 4
with copy number breakpoints. We allowed a 100 Kb window to the expected orientation for both 1 3 5
partner genes when searching array based copy number data. 1 3 6
We detected structural variants (SVs) 19 from whole genome sequencing (WGS) data using 1 3 7
Speedseq with default parameters. We filtered SVs requiring more than 3 supporting reads, i.e. at least 1 3 8
one split read and one discordant read pair. For fold-back inversions (BND on the same chromosome) 1 3 9
we required more than 9 supporting reads. We removed SVs with breakpoints falling in low-complexity 1 4 0
regions (e.g. repeat region DNA), or stacking across different tumor types. We further removed SVs 1 4 1
where the flanking 100 bp of the two breakpoints share high sequence similarity (blastn E-value > 1 4 2 0.0001). Germline events were filtered out by comparing with matched normal samples. 1 4 3
We scanned the intersection between the edge of confident interval from the supported 1 4 4 structure variants including large fragment duplication, deletion, insertion and inversion and truncated 1 4 5
intron region flanking the junction upon fusion events. We assigned two partner genes into three groups 1 4 6
based on their relevant location of break points to adjacent break point of structure variants. High 1 4 7 confidence group was defined when a break point of structure variants fell into the immediate intron of 1 4 8 the fusing exon for both partner genes; low confidence group was defined when a break point of 1 4 9 structure variants fell between the fusion junction and the start or end of the partner gene depending on 1 5 0 the fusion orientation, or fell into the 100K window from the corresponding gene boundary; Intermediate 1 5 1 confidence group was defined when one partner gene met criteria of high confidence group and the 1 5 2 other met that of the low confidence group. For those fusion pairs with only one junction points 1 5 3 supported by structure variants, we assigned as one-sided. 1 5 4 1 5 5
Exons and transcription expression analysis of fusions 1 5 6
Exons and transcripts expression of fusion partners are retrieved from normalized RSEM value of 1 5 7 level3 RNA-seq from Firehose (https://gdac.broadinstitute.org/). We performed Z score transformed 1 5 8 expression level across all samples in each cancer type to plot exon expression heatmaps. 1 5 9 1 6 0 Fusion centrality analysis 1 6 1 Fusion transcript centrality score was calculated based on domain-based fusion model using default 1 6 2 parameters (https://bmsr.usc.edu/software/targetgene/), to predict the oncogenic driver in which partner 1 6 3 genes act as hubs in a cancer pathway network 12 . Fusions with centrality score > 0.37 were 1 6 4 considered as potential drivers. 
